Abstract: The present invention relates to a compound of formula (I) a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein R1 represents hydrogen, C1-6alkyl, C3-7cycloalkyl, C1-6alkyloxyC1-6alkyl, di(C1-6alkyl)aminoC1-6alkyl, aryl or heteroaryl; each R2 independently represents halo, C1-6alkyl, C1-6alkyloxy, C1-6alkylthio, polyhaloC1-6alkyl, polyhaloC1-6alkyloxy, cyano, aminocarbonyl, amino, mono- or di(C1-4alkyl)amino, nitro, aryl or aryloxy; R3 represents hydrogen, cyano, C1-6alkyl optionally substituted with hydroxy or C1-6alkyloxy, C(?O)—O—R6, C(?O)—NR7aR7b, C(?S)—NR7aR7b, S(?O)2—NR7aR7b or C(?O)—R8; R4 represents hydrogen, cyano, C1-6alkyl optionally substituted with hydroxy or C1-6alkyloxy, C(?O)—O—R6, C(?O)—NR7aR7b, C(?S)—NR7aR7b, S(?O)2—NR7aR7b or C(?O)—R8; or R3 and R4 taken together may form a bivalent radical of formula —C(?O)—NH—NH—C(?O)—; n is 1, 2, 3, 4 or 5; provided that at least one of R3 or R4 is other than hydrogen; and

Abstract: The present invention relates to a compound of formula (I) having CCR2 receptor antagonistic properties, particularly anti-inflammatory properties.

Abstract: The present invention is concerned with the finding that farnesyl protein transferase inhibitors are useful for preparing a pharmaceutical composition for treating arthropathies such as rheumatoid arthritis, osteoarthritis, juvenile arthritis, and gout.